These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 2605826)
21. Side and type of motor symptom influence cognition in Parkinson's disease. Katzen HL; Levin BE; Weiner W Mov Disord; 2006 Nov; 21(11):1947-53. PubMed ID: 16991155 [TBL] [Abstract][Full Text] [Related]
22. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733 [TBL] [Abstract][Full Text] [Related]
23. Motor procedural learning in Parkinson's disease. Muslimovic D; Post B; Speelman JD; Schmand B Brain; 2007 Nov; 130(Pt 11):2887-97. PubMed ID: 17855374 [TBL] [Abstract][Full Text] [Related]
24. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Sato K; Hatano T; Yamashiro K; Kagohashi M; Nishioka K; Izawa N; Mochizuki H; Hattori N; Mori H; Mizuno Y; Mov Disord; 2006 Sep; 21(9):1384-95. PubMed ID: 16763980 [TBL] [Abstract][Full Text] [Related]
25. Global Mobility Task: index for evaluating motor impairment and motor rehabilitation programs in Parkinson's disease patients. Peppe A; Ranaldi A; Chiavalon C; Gasbarra A; Collepardo A; Romeo R; Pasqualetti P; Caltagirone C Acta Neurol Scand; 2007 Sep; 116(3):182-9. PubMed ID: 17714332 [TBL] [Abstract][Full Text] [Related]
26. [Depressive symptoms and motor condition in Parkinson's disease patients]. Stella F; Bucken-Gobbi LT; Gobbi S; Sant'Ana-Simões C Rev Neurol; 2007 Nov 16-30; 45(10):594-8. PubMed ID: 18008264 [TBL] [Abstract][Full Text] [Related]
27. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451 [TBL] [Abstract][Full Text] [Related]
28. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey]. Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R; Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176 [TBL] [Abstract][Full Text] [Related]
29. [Parkinson's disease and mental deterioration. Apropos of 30 cases]. Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N Ann Med Psychol (Paris); 1983 Nov; 141(9):945-56. PubMed ID: 6666920 [TBL] [Abstract][Full Text] [Related]
30. The validity of the GaitRite and the Functional Ambulation Performance scoring system in the analysis of Parkinson gait. Nelson AJ; Zwick D; Brody S; Doran C; Pulver L; Rooz G; Sadownick M; Nelson R; Rothman J NeuroRehabilitation; 2002; 17(3):255-62. PubMed ID: 12237507 [TBL] [Abstract][Full Text] [Related]
31. [Executive function in Parkinson's disease]. Kanazawa A; Mizuno Y; Narabayashi H Rinsho Shinkeigaku; 2001; 41(4-5):167-72. PubMed ID: 11676156 [TBL] [Abstract][Full Text] [Related]
32. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms. Doan JB; Melvin KG; Whishaw IQ; Suchowersky O Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094 [TBL] [Abstract][Full Text] [Related]
33. Cognition in Parkinson's disease. Basić J; Katić S; Vranicć A; Zarevski P; Babić T; Mahović-Lakusić D Croat Med J; 2004 Aug; 45(4):451-6. PubMed ID: 15311418 [TBL] [Abstract][Full Text] [Related]
34. Effect of selegiline on cognitive functions in Parkinson's disease. Dixit SN; Behari M; Ahuja GK J Assoc Physicians India; 1999 Aug; 47(8):784-6. PubMed ID: 10778622 [TBL] [Abstract][Full Text] [Related]
35. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079 [TBL] [Abstract][Full Text] [Related]
36. [A study of attitudes toward illness and its effect on mortality in patients with Parkinson's disease]. Kuroda K; Tatara K; Shinsho H; Okamoto E; Cho R; Nishigaki C; Takatorige T; Nakanishi N; Aoki T Nihon Koshu Eisei Zasshi; 1990 May; 37(5):333-9. PubMed ID: 2131994 [TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up review of cases of Parkinson's disease after unilateral or bilateral thalamotomy. Matsumoto K; Shichijo F; Fukami T J Neurosurg; 1984 May; 60(5):1033-44. PubMed ID: 6716138 [TBL] [Abstract][Full Text] [Related]
39. Non-existence of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin in patients with Parkinson's disease. Inagaki T; Shikimi T; Matsubara K; Kobayashi S; Ishino H; Okunishi H; Takaori S Psychiatry Clin Neurosci; 1996 Aug; 50(4):231-3. PubMed ID: 9201781 [TBL] [Abstract][Full Text] [Related]
40. The effect of symptom duration on cognitive and motor performance in parkinsonism. Matthews CG; Haaland KY Neurology; 1979 Jul; 29(7):951-6. PubMed ID: 572944 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]